Industry
Biotechnology
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 28, 2024 | 11:02 am
Portfolio Pulse from Benzinga Newsdesk
August 28, 2024 | 11:02 am
Portfolio Pulse from Vandana Singh
August 28, 2024 | 11:00 am
Portfolio Pulse from Benzinga Newsdesk
August 16, 2024 | 8:14 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 6:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 1:22 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 12:03 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 2:20 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 1:02 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.